With the opioid crisis in full force and doctors feeling pressure to cut back on the number of opioid painkillers they prescribe, chronic-pain patients aren’t left with many alternatives that are as effective or accessible. So the pharmaceutical industry is looking to bring more non-opioid pain medications into market, with 17 drugs in late-stage clinical development and 40 drugs in early-stage development. One of the new types of drugs is used to block the nerve-growth factor, which can reduce pain in patients with osteoarthritis, chronic back pain, and cancer pain. The two newsworthy drugs in this category are tanezumab and fasinumab. Centrexion, a capsaicin-derived drug, has also received buzz for its pain-reducing properties.
Debbie Page, 66, has suffered from chronic pain for half of her life after a back injury left her with the inability to stand for more than a few minutes at a time.
“After an hour I can’t think or see,” she said. “The pain takes over and it’s torture.”See the rest of the story at Business Insider